Potential influence of international harmonization of pharmaceutical regulations on biopharmaceutical development

Current Opinion in Biotechnology

Volumn 8, Issue 3, 1997, Pages 350-356

  Lubiniecki, Anthony S ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DRUG CONTROL; DRUG DEVELOPMENT; DRUG STABILITY; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030962084     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(97)80016-X     Document Type: Article

References (30)

1. International Conference on Harmonization, Expert Working Group on Biotechnology Quality. Quality of Biotechnological Products: stability Testing of Biotechnological/Biological Products. Fed Reg 1998 61:36466-36469.
2. International Conference on Harmonization, Expert Working Group on Biotechnology Quality. Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of rONA Derived Protein Products. Fed Reg 1996, 61:7006-7008.
3. Chiu YY: Genetic stability of rDNA production systems, a case report. Dev Biol Standard 1994, 83:93-97.
4. Committee on Process Development and Manufacturing, Pharmaceutical Manufacturers Association: Assessment of genetic stability of biotechnology products. Bio/Pharm 1991, 4:22-27.
5. Garnick R, Helder JC: Report on the genetic stability symposium West Coast chapter, parenteral drug association. Dev Biol Standard 1994, 83:177-178.
6. US Department of Health and Human Services, Food and Drug Administration, Center for Drugs and Biologics, Office of Biologic Research and Review: Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology. Rockville: FDA: 1985.
7. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research: Supplement to Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology. Nucleic Acid Characterization and Genetic Stability. Rockville: FDA; 1992.
8. Galibert F: Stability of a gene recombinant: what does it mean and how to check for it? Biologicals 1990, 18:221-224.
9. Galibert F: Letter to the editor. Biologicals 1990, 18:355.
10. Burstyn D, Copmann T, Dinowitz M, Garnick R, Losikoff A, Lubiniecki A, Wiebe M: Genetic stability and recombinant product consistency. Biologicals 1993, 21:147-149.
11. Burstyn D, Copmann T, Dinowitz M, Garnick R, Losikoff A, Lubiniecki A, Rubinio M, Wiebe M: Assessment of genetic stability for biotechnology products. Biopharm 1991, 4:25-30.
12. Brown F, Lubiniecki A (Eds): Genetic Stability and Recombinant Product Consistency. Basel: Karger; 1994.
13. Rosenberger R: Translational errors during recombinant protein synthesis. Dev Biol Standard 1994, 83:21-26.
14. Rohde M, Lu H, Rush R: Peptide mapping of recombinant proteins. Dev Biol Standard 1994, 83:121-127.
15. Horaud F, Lubiniecki A, Robertson J: Meeting summary. Dev Biol Standard 1994, 83:187-193.
16. O'Connor J, Keck R, Harris R, Field M: New techniques in protein chemistry. Dev Biol Standard 1994, 83:165-173.
17. International Conference of Harmonization, Expert Working Group on Biotechnology Quality: Draft Guideline on Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. Fed Reg 1996, 61:21882-21891.
18. Centers for Disease Control: Possible transfusion-associated acquired immunodeficiency syndrome (AIDS)-California. Morbid Mortal Weekly Rep 1982, 31:652-654.
19. Centers for Disease Control: Provisional Public Health Service inter-agency recommendations for screening donated blood and plasma for antibody to the virus causing acquired immunodeficiency syndrome. Morbid Mortal Weekly Rep 1985, 34:1-5.
20. Horowitz B, Prince A, Horowitz M, Watklevicz C: Viral safety of solvent-detergent-treated blood products. Dev Biol Standard 1993,81:147-161.
21. Nowak T, Niedrig M, Bernhardt D, Hilfenhaus J: Inactivation of HIV, HBV, HCV, HCV related viruses and other viruses in human plasma derivatives by pasteurization. Dev Biol Standard 1993, 81:169-176.
22. Commission of the European Communities: Validation of Virus Removal and Inactivation Procedures. February 1991. Brussels: European Commission; 1991. [III/8115/89-EN Final].
23. Commission of the European Communities: Medicinal Products Derived from Human Blood and Plasma. December 1991. Brussels: European Commission; 1991 [III/8379/89-EN Final.]
24. Burstyn D: Contamination of genetically engineered Chinese hamster ovary cells. Dev Biol Standard 1996, 88:199-203.
25. Nettleton P, Rweyemamu M: The association of calf serum with the contamination of BHK21 suspension cells by a parvovirus serologically related to Minute Virus of Mice (MVM). Arch Virol 1980, 64:359-374.
26. Garnick R: Experience with viral contamination in cell culture. Dev Biol Standard 1996, 88:49-56.
27. Lubiniecki A: Survey of manufacturers and developers of cell culture-derived products for evidence of adventitious contamination. Dev Biol Standard 1996, 88:195-197.
28. International Conference on Harmonization Expert Working Group on Biotechnology Quality. Quality of Biotechnological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products. January 1997. International Conference on Harmonization, Geneva.
29. Expert Committee on Biological Standardization: Requirements for Use of Animal Cells as in vitro Substrates for the Production of Biologicals. October 1996. World Health Organization, Geneva.
30. International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use: Preclinical Testing of Biotechnology-Dervied Pharmaceuticals. November 1996. International Conference on Harmonization, Geneva.